JSC Grindeks extends its product range offering new generation medicine for the treatment of schizophrenia

From this 10th of December, JSC Grindeks begins to offer Rispaxol® - the
qualitative new generation medicine for the treatment of schizophrenia. This
medicine will be included in the List of reimbursable medical products of
Latvia with its reference price, and from 1 January 2008 schizophrenia patients
will have been being reimbursed for purchase expenses of 100%. 

Grindeks keeps observing continuously the tendencies on pharmaceutical market,
responding to them quickly and actively to offer consumers new medicines
necessary to meet their needs. 
„I am satisfied with our ability to offer to Latvian market high quality
effective product manufactured by domestic producer, and complying with all and
any modern international requirements and quality standards. The new medicine
will be effective measure in struggling against disastrous disease;
furthermore, we have found a possibility to offer it to the state for the most
beneficial price. Introduction of Rispaxol® shows Grindeks as a company having
obtained considerable achievement in extending its product range,” pointed
Jānis Romanovskis, Chairman of the Board of Grindeks. 

Perspective development and promotion of generics which will have been carrying
out on the market soon after expiration of a patent covering original products,
is the one of strategic directions of the Grindeks's new products development.
Rispaxol® is bioequivalent* to the original product Risperidonum, which had
been task-oriented created to fight effectively against schizophrenia - one of
the gravest mental diseases. 

According to the World Health Organization statistical data, schizophrenia is
one of the most prevalent insanities, and 1% of the population of the world is
affected with it, regardless of economic conditions in the state, irrespective
of continent and climate.  The incidence of this disease, diagnosed in Latvia
is approximately 19 000**. 

Grindeks has intended to start a promotion of Rispaxol® in Russia and countries
of Commonwealth of Independent States from 2008. 

JSC Grindeks is the leading pharmaceutical company in Baltic States,
specializing in the research, development, manufacturing and sales of heart and
cardiovascular, central nervous system and anti-cancer medications. A range of
Grindeks's products covers a successful combination of original products and
generics, with the original products Mildronate® and Ftorafur® and more than
100 forms of effective and safe generics included therein. 

Grindeks concern consists of four subsidiary companies in Latvia, Estonia and
Russia as well as ten representative offices. Products of the company are
exported to more than 40 countries. Main markets are the Baltic States, Russia
and CIS countries, Japan, USA. Grindeks shares are listed in the Official List
of Riga Stock Exchange. 


Laila Kļaviņa
Manager of the Communications Department of JSC Grindeks 
Phone: 7083370
Mob. phone: 29256012
laila.klavina@grindeks.lv


* If two or more similar dosage forms of a drug reach the general circulation
at the same relative rate and the same relative extent, they are bioequivalent 
** Sources - The Business Activity Report of State Mental Health Agency  and
data base of Central Statistics Board.